Cue Biopharma Receives Positive FDA Feedback for CUE-401 Autoimmune Therapy, Advances Toward IND Filing
Cue Biopharma received positive Pre-IND feedback from the FDA for CUE-401, a first-in-class bispecific fusion protein designed to treat autoimmune diseases by inducing regulatory T cells.
Boehringer Ingelheim and Cue Biopharma Partner on Novel B Cell-Targeting Therapy for Autoimmune Diseases
Boehringer Ingelheim and Cue Biopharma have formed a strategic partnership to develop CUE-501, a first-in-class bispecific therapy designed to selectively deplete disease-causing B cells in autoimmune conditions.
Cue Biopharma's CUE-101 and CUE-102 Show Promise in Phase 1 Trials for Head and Neck and WT1-Positive Cancers
CUE-101 combined with pembrolizumab demonstrates a 46% objective response rate and a 91.3% 12-month overall survival rate in first-line HPV+ R/M HNSCC patients.
Cue Biopharma's CUE-101 and CUE-102 Show Promising Phase 1 Results in Cancer Trials
Cue Biopharma's CUE-101, combined with pembrolizumab, demonstrated a 46% objective response rate and a 91.3% 12-month overall survival rate in head and neck cancer patients.
Cue Biopharma Announces Positive Phase 1 Data for CUE-101 and CUE-102 at SITC 2024
CUE-101 combined with pembrolizumab shows a 46% objective response rate and 91.3% 12-month overall survival in first-line HPV+ recurrent/metastatic head and neck squamous cell carcinoma patients.